Oncoinvent ASA (7BG) Stock Statistics & Valuation Metrics

Oncoinvent ASA has a market cap or net worth of €36.01M. The enterprise value is -€99.84.

Oncoinvent ASA has 4,478,412 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oncoinvent ASA’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -94.56%.

The current PE Ratio of Oncoinvent ASA is ―. Oncoinvent ASA’s PEG ratio is ―.

In the last 12 months, Oncoinvent ASA had revenue of 23.04M and earned -155.07M in profits. Earnings per share was -125.13.

In the last 12 months, operating cash flow was -127.15M and capital expenditures -120.00K, giving a free cash flow of -127.27M billion.

Oncoinvent ASA pays an annual dividend of ―, resulting in a dividend yield of ―

Oncoinvent ASA upcoming earnings date is Aug 27, 2026, TBA (Confirmed).

Oncoinvent ASA as a current ratio of 3.23, with Debt / Equity ratio of 2.43%

In the past 12 months, Oncoinvent ASA has paid 0.00 in taxes.

Oncoinvent ASA EV to EBITDA ratio is 0.87, with an EV/FCF ratio of 0.89.

Oncoinvent ASA has €177.60M in cash and marketable securities with €818.00K in debt, giving a net cash position of €174.05M billion.

Gross margin is -204.27%, with operating margin of -615.20%, and net profit margin of -673.13%.

The average price target for Oncoinvent ASA is ―, which is 11.43% higher than the current price. The consensus rating is ―